Catalent has formed an agreement with Biohaven Pharmaceutical Holding Company, the parent company of Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company, to provide Catalent's Zydis orally disintegrating tablet (ODT) technology for developing a fast-dissolving formulation for Biohaven's lead product candidate, rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist for treating migraines. The agreement also provides Biohaven exclusive rights for developing small-molecule CGRP receptor antagonists with the Zydis ODT technology. Catalent's proprietary Zydis technology is a freeze-dried, oral solid-dosage form that is designed to disperse almost instantly in the mouth without the need for water, according to information from the companies.